(Total Views: 546)
Posted On: 06/12/2022 11:39:06 AM
Post# of 154723
In fact, according to one report, 50% of HIV patients are now multidrug resistant.
Gestalt suggested that we might get 10% of the HIV market. Seems entirely reasonable.
So when suncloud says "our trial was for MDR or multi drug resistant patients which would not include all patients just those who failed with multiple other treatments," this is a far larger group than Gestalt's 10%.
There is still an HIV market for Leron.
Gestalt suggested that we might get 10% of the HIV market. Seems entirely reasonable.
So when suncloud says "our trial was for MDR or multi drug resistant patients which would not include all patients just those who failed with multiple other treatments," this is a far larger group than Gestalt's 10%.
There is still an HIV market for Leron.
(6)
(0)
